LifeSci Capital Initiates Coverage of Albireo

Lead Product A4250 is Being Investigated for Multiple Pediatric Orphan Liver Diseases
Report Available here: http://www.lifescicapital.com/equity-research/albireo/

NEW YORK, NY / ACCESSWIRE / November 16, 2016 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of Albireo (NasdaqCM: ALBO), a clinical-stage biotechnology company focused on the development of bile acid modulators for the treatment of liver and gastrointestinal diseases. The Company’s lead drug candidate, A4250, is being developed for the treatment of several cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC). It is in a Phase II trial for pediatric cholestatic pruritus, which is expected to report data from the fifth of six cohorts in the fourth quarter of 2016. Albireo recently completed a share exchange agreement with Biodel, which functioned as a reverse merger and capitalized the Company with $30 million from the transaction and concurrent insider financing. Albireo is now trading publicly under the symbol ALBO and has sufficient capital to fund a planned pivotal trial with A4250 for PFIC.

Albireo is developing A4250 for the treatment of a range of cholestatic liver diseases, with an initial focus on targeting progressive familial intrahepatic cholestasis (PFIC). The Company also plans to develop A4250 for biliary atresia (BA), primary biliary cirrhosis (PBC), and pediatric cholestatic pruritus. There is currently a Phase II trial for this compound underway in pediatric cholestatic pruritus, and interim results demonstrate dose-dependent decreases in serum bile acid levels and there have not been any serious adverse events reported. Patients in the most recent cohort who received the highest dose of A4250 (0.1 mg/kg) experienced a 46% mean decrease in serum bile acids as compared to baseline levels. The Company expects to report additional data in the fourth quarter of 2016.

In a 37 page Initiation Report, LifeSci Capital describes the Company’s treatment for pediatric cholestatic liver diseases, how the product is differentiated from other therapies, and the large market opportunity for PFIC as well as other indications.

Dr. Isaacson’s full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on Albireo as developments occur.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients’ businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company’s website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC

ReleaseID: 449200